It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The appointment is effective from May 01, 2023 for five years
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
